The President & CEO of Luminex (NASDAQ: LMNX) is Buying SharesBy Carrie Williams
Following this transaction Nachum Shamir’s holding in the company was increased by 6.06% to a total of $1.96 million. In addition to Nachum Shamir, 2 other LMNX executives reported Buy trades in the last month.
Based on Luminex’s latest earnings report from September 30, the company posted quarterly revenue of $71.22M and quarterly net profit of $2.75M. In comparison, last year the company earned revenue of $60.6M and had a net profit of $6.4M. The company has a one year high of $23.75 and a one year low of $17.29. LMNX’s market cap is $788.4M and the company has a P/E ratio of 21.22.
Based on 3 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $24.50, reflecting a -24.7% downside. Five different firms, including Avondale and Citigroup, currently also have a Buy rating on the stock.
The insider sentiment on Luminex has been positive according to 23 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.
Luminex Corp. develops, manufactures and markets proprietary biological testing technologies and products with applications throughout the life sciences and diagnostics industries. Luminex was founded by Mark B. Chandler and Van S. Chandler in May 1995 and is headquartered in Austin, TX.